GoodRx Holdings, Inc. (Nasdaq: GDRX) has announced the election of Ronald E. Bruehlman to its board of directors, effective November 8, 2024. Mr. Bruehlman, currently serving as the Chief Financial Officer of IQVIA, brings 39 years of finance experience in the healthcare services, industrial, and petroleum industries to GoodRx.
Trevor Bezdek, GoodRx co-founder and chairman of the board, expressed excitement about Mr. Bruehlman's appointment, citing his extensive expertise in leading financial strategies for public and private healthcare and technology companies. Mr. Bezdek highlighted the importance of Mr. Bruehlman's financial insight and strategic acumen as GoodRx continues to focus on sustainable and profitable revenue growth, aiming to enhance affordability and access to prescription medications across the country.
In addition to his role on the board, Mr. Bruehlman will also serve as the chairperson of the board’s audit and risk committee, following the resignation of Julie Bradley as a member of GoodRx’s board of directors.
GoodRx is the leading prescription savings platform in the U.S., trusted by more than 25 million consumers and 750,000 healthcare professionals annually. The platform provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide and offers comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.
These changes in the board of directors come as GoodRx continues to position itself as a leader in the prescription savings space, aiming to drive sustainable and profitable revenue growth while enhancing affordability and access to prescription medications for consumers across the country. Today the company's shares have moved 1.8% to a price of $6.32. Check out the company's full 8-K submission here.
